



Published in final edited form as:

Curr Sex Health Rep. 2019 September ; 11(3): 190–200. doi:10.1007/s11930-019-00210-1.

Minimizing Sexual Dysfunction in BPH Surgery

Joon Yau Leong¹, Amir S. Patel², Ranjith Ramasamy³

¹Department of Urology, Sidney Kimmel Medical College, Thomas Jefferson University, 1025 Walnut Street, College Building, Suite 1112, Philadelphia, PA 19107, USA

²Department of Urology, Oregon Health and Science University, Portland, OR, USA

³Department of Urology, University of Miami Miller School of Medicine, Miami, FL, USA

Abstract

Purpose of Review—To review the prevalence and risks of sexual dysfunction associated with current treatment options for benign prostatic hyperplasia and to characterize techniques and methods to manage postoperative sexual dysfunction-related side effects.

Recent Findings—Current surgical therapies available for the treatment of benign prostatic hyperplasia are associated with a substantial risk of both ejaculatory and erectile function. However, many of the novel minimally invasive treatment alternatives have demonstrated the ability to preserve postoperative sexual function to a better degree, all while providing significant relief of lower urinary tract symptoms in an equally safe and efficacious manner.

Summary—Benign prostatic hyperplasia remains a highly prevalent disease among the aging population. While surgical treatments are often necessary to relieve bothersome urinary symptoms, these procedures are associated with an increased risk of sexual dysfunction. As such, there has been an increased interest in the development of minimally invasive therapies, such as the UroLift®, Rezum®, and Aquablation®, with the hopes of achieving similar symptomatic relief while maintaining sexual function. Aside from reporting lower rates of sexual dysfunction, these procedures have also demonstrated comparable safety, durability, and efficacy to current gold standard therapies. Some procedures can even be performed in an outpatient setting, avoiding the need for general anesthesia altogether. Overall, an individualized, shared decision-making approach is necessary to determine the ideal treatment option for each patient.

Keywords

Benign prostatic hyperplasia; Lower urinary tract symptoms; Sexual dysfunction; Erectile dysfunction; Ejaculatory dysfunction

Joon Yau Leong, joonyau.leong@jefferson.edu.

This article is part of the Topical Collection on *Male and Female Surgical Interventions*

Conflict of Interest The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Introduction

Benign prostatic hyperplasia (BPH) resulting in lower urinary tract symptoms (LUTS) is a major health burden affecting 50% of men over 60 years and 80% of men over 80 years [1]. With the proliferation of epithelial and smooth muscle cells within the transitional zone of the prostate, urinary flow resistance through the prostatic urethra increases, leading to irritative (nocturia, urgency, frequency) and obstructive (hesitancy, dribbling, weak stream) symptoms. The treatment for LUTS secondary to BPH includes medical therapies, surgical interventions, or observation alone. In men with moderate to severe symptoms, however, medical or surgical management is often recommended as this reduces the risk for disease progression as well as improves the individual's quality of life (QoL). Unfortunately, the surgical treatment of BPH is not without its inherent risks, with one of its major adverse effects being the increased risk of sexual dysfunction.

Interestingly, the direct association between sexual dysfunction and the effects of LUTS secondary to BPH has been well established. A multinational survey conducted by Rosen et al. in 2003 demonstrated that sexual problems such as erectile dysfunction and ejaculatory disorders were strongly related to both patient age and the severity of LUTS [2]. This suggests the complex interplay between this disease entity and sexual dysfunction. Conversely, many cavitating procedures aimed at treating BPH to improve LUTS also run the risk of developing sexual dysfunction [3••].

As sexual activity remains an essential component of overall QoL in most men regardless of age, the benefits of more invasive interventions to increase the efficacy of relieving LUTS must be weighed against the cost and risks of developing sexual dysfunction [4]. As such, newer technologies attempting to strike the balance of achieving improved efficacy and decreased sexual dysfunction is constantly underway. The knowledge of current treatment modalities and its accompanying side effect profiles are paramount to the present-day urologist for education and counseling of a patient (Tables 1 and 2).

Herein, we aim to provide a contemporary review on the prevalence and underlying pathophysiology of developing sexual dysfunction with current surgical modalities available for BPH. We further characterize specific techniques to minimize sexual dysfunction in these surgical interventions while also describing the use of novel, minimally invasive treatment alternatives which are safer, cost-effective, and equally efficacious.

What Do We Know About Sexual Dysfunction?

Although BPH remains a highly prevalent disease among the aging population, a majority of men choose to seek medical advice only after experiencing bothersome urinary symptoms [15]. While oral therapy with α -blockers or 5- α reductase inhibitors (5ARIs) are the most common initial treatment for men with LUTS, surgical intervention remains an appropriate alternative in patients with particularly bothersome LUTS or in patients with BPH-related complications, e.g., acute urinary retention. Surgical treatments for LUTS have been shown to provide immediate improvement in alleviating BPH symptoms but have the highest risk of developing sexual dysfunction when compared to other therapeutic options.

While the International Index of Erectile Function (IIEF) and Male Sexual Health Questionnaire (MSHQ) scores are objective methods to compare and assess sexual outcomes, clinicians need to take into consideration that most of these BPH patients often already suffer from some degree of preoperative sexual dysfunction, which includes both erectile dysfunction (ED) and ejaculatory dysfunction (EjD). EjD further encompasses multiple ejaculatory and orgasmic symptoms, most commonly in the form of retrograde ejaculation (REj), but also includes premature ejaculation, delayed ejaculation, anejaculation, painful ejaculation, and decreased strength and volume of ejaculate or decreased feelings of pleasure associated with ejaculation [16].

Over the last few decades, novel surgical alternatives to BPH are increasingly emerging, with the goal of achieving similar outcomes to improving LUTS while minimizing sexual side effects. Among these, Aquablation®, prostatic artery embolization (PAE), and in-office procedures such as the UroLift® and Rezum® technology report promising results regarding sexual function preservation.

Why Do Surgeries for BPH Lead to Sexual Dysfunction?

Going through surgery for BPH can negatively impacts sexual desire, arousal, and satisfaction. There are a multitude of reasons why this occurs. Surgery can have a negative psychosocial impact on a patient. A 2017 study by Cornell et al. looked at sexual dysfunction in women after breast cancer surgery which showed a significant decrease in the Female Sexual Function Index (FSFI) score in women who had unilateral mastectomies including those who underwent breast-conserving surgery. This study highlights the impact of psychosocial factors on sexual function after surgeries [17].

In prostate-cavitating surgeries such as the transurethral resection of the prostate, sexual dysfunction can occur when the neurovascular bundles are accidentally dissected or damaged during the procedure. Anterograde ejaculation requires contraction of the external sphincter and bulbar urethra to propel the ejaculate forward and outward into the environment. In 1994, this was proven with a recorded ultrasound video of the proximal urethra during ejaculation, showing the importance of these muscles. When the mechanism to push the ejaculate forward is damaged or disrupted intraoperatively, semen will enter through the bladder neck instead of the urethra and can only be expelled during micturition, hence the term retrograde ejaculation [18].

While ejaculatory disorders are agreed to be a common adverse effect after surgery for BPH, the verdict on erectile function is more controversial. One potential mechanism of postoperative ED is the indirect thermal injury to the erectile nerves. Additionally, some studies also suggest a psychosocial component [19, 20]. Unfortunately, much of this is anecdotal and many modern studies do not show any significant decline in erectile function [21, 22]. Even studies that do show a decrease report lower incidence rates of ED (0–32%) as compared to that of EjD (> 50%) [23]. Some studies further suggest that only men with normal preoperative erectile function will suffer from a significant decrease in IIEF scores after treatment [24]. Overall, despite some evidence demonstrating ED after BPH

procedures, EjD is much more common and remain the primary cause of patient dissatisfaction.

In addition, in non-oncology-related surgeries, a study in 2001 showed that anterior urethroplasties and circumcisions both resulted in a 30.9% and 27.3% decrease in erection satisfaction, respectively. The authors suggested that this may be due to the location of the wound, with it being more visible in those after a circumcision, again confirming the role and impact of psychosocial factors on sexual function [25].

BPH Surgeries and Sexual Dysfunction

Transurethral Resection of the Prostate

Although the association of EjD to transurethral resection of the prostate (TURP) has been firmly established, this surgical technique—first described in the early 1900s—remains the gold standard therapy for the surgical management of BPH [26]. In larger prostates over 100 g, open, robotic, or laparoscopic simple prostatectomies may be performed as well. Recent randomized controlled trials have reported a 62–75% incidence rate of EjD, specifically retrograde ejaculation, among patients undergoing TURP [27, 28, 29]. This is consistent with the 65% reported by the 2018 AUA BPH guideline panel members [26]. Conversely, a 13–14% risk of ED was also associated with TURP with a study by Taher et al. demonstrating a higher risk of postoperative ED with lower preoperative nocturnal penile tumescence parameters [27, 30]. The volume of resected prostate or the use of either monopolar or bipolar TURP was not associated with an increased risk of sexual dysfunction [31–34, 35]. With regard to other adverse effects, it is important to note that there is an increased risk of urinary incontinence if a TURP is performed in patients who have undergone brachytherapy for prostate cancer [36, 37].

Holmium Laser Enucleation of the Prostate

The Holmium laser, first described by Gilling et al. for the treatment of BPH, emits a 2140-nm wavelength which is selectively absorbed by water which can be used to resect or enucleate prostatic adenomas [38]. While randomized controlled trials have described similar efficacy of Holmium laser enucleation of the prostate (HoLEP) to open prostatectomy in enucleating adenomas over 100 g with its inherent advantages of decreased blood loss and hospital stays, this procedure is not without its risks [39]. A study by Meng et al. demonstrated a 21% risk of painful ejaculation and a 70% rate of REj on 6-month follow-up after HoLEP but no significant differences in erectile function and orgasm rates [40]. Interestingly, there was an increase in early morning erections in 15% of patients who underwent HoLEP. When comparing HoLEP and the gold standard TURP, Briganti et al. found that postoperative erectile function and rates of REj and decreased ejaculate volume did not differ significantly between the two procedures. However, rates of REj, decreased ejaculatory volume, and painful ejaculation were reported to be 76.6%, 18.3%, and 3.3% respectively at 1-year follow-up after HoLEP. Utilizing the International Index of Erectile Function (IIEF) questionnaire, the authors found a slight increase in erectile function score but a significant decrease in orgasmic function domain score postoperatively. The objective decrease in orgasmic function is likely due to the increased prevalence of REj and decreased

ejaculatory function. Conversely, the positive correlation between IIEF-erectile function scores to improved IPSS and QoL scores within their study suggests the potential influence of postoperative relief of LUTS and QoL amelioration on increased erection ability [41]. Ultimately, a meta-analysis by Zong et al. found no significant differences in sexual dysfunction when comparing HoLEP to TURP [42]. Due to its excellent hemostatic properties and decreased morbidity in patients with prostates over 100 g, the HoLEP can be considered an effective treatment for BPH after patients are well educated and counseled regarding the potential side effects of the procedure.

Photoselective Vaporization of the Prostate

Utilizing light wavelengths of 532 nm, which is preferentially absorbed by hemoglobin, the GreenLight laser has emerged as an alternative therapy to TURP for the treatment of BPH via rapid vaporization of the transitional zone of the prostate [26, 43•]. Results from the GOLIATH prospective trial comparing GreenLight photoselective vaporization of the prostate (PVP) to TURP showed no significant difference between rates of REj and IIEF-5 scores between the two procedures at the 1- and 2-year follow-ups, respectively [44, 45]. Incidence of new-onset REj rates were reported at 30–67.1% with an additional 5.4% risk of developing painful ejaculation after PVP [44, 46, 47]. Although single institutional studies have shown no detrimental effects of PVP on erectile function, a recent meta-analysis by Li et al. demonstrated that of the nine BPH procedures analyzed, PVP was the only one to negatively impact short-term postoperative erectile function [46, 48, 49]. It is also important to note that studies utilizing higher laser energy levels have a higher propensity to developing sexual dysfunction [19].

Transurethral Microwave Therapy/Transurethral Needle Ablation

Given its markedly lower side effect profile, its ability to be performed as an outpatient procedure and its efficacy in providing reasonable symptom reduction, the use of minimally invasive procedures such as transurethral microwave therapy (TUMT) and transurethral needle ablation (TUNA) are gaining in popularity for the treatment of BPH [50, 51]. The incidence of ED after TUMT and TUNA is minimal and the risk of REj after these procedures remain low as compared to TURP. A systematic review by Friebe et al. found that TUNA was associated with only a 5.6% and 5.8% risk of EjD and ED, respectively. Conversely, TUMT had a lower post-procedure sexual dysfunction rate when compared to TURP with an 8.7% risk of developing ED and 17.8% risk of developing EjD. This was decreased to 11%, upon 24-month follow-up [35•]. Despite considerable improvements in their LUTS, patients who undergo TUMT/TUNA do not match TURP for objective improvement of IPSS and Qmax [52–54]. Thus, these treatment modalities may be considered as an alternative option in younger patients who wish to preserve sexual function [55•].

Newer Therapies for BPH

Prostatic Urethral Lift

The prostatic urethral lift (PUL), performed with the UroLift® system (NeoTract, Pleasanton, CA, USA), is a considerably novel yet minimally invasive technique that utilizes

permanent nitinol and stainless steel implants placed under cystoscopic guidance to retract the obstructing lateral lobes of the prostate. It has demonstrated considerable safety and efficacy in the improvement of LUTS in patients with small- to medium-sized prostates (< 80 g) but is not ideal in patients with obstructing median lobes. Moreover, PUL is known to preserve sexual function with no evidence to date reporting any incidence of ED or EjD [56–59]. The largest prospectively collected PUL data from the LIFT study by Roehrborn et al. demonstrated no significant changes in MSHQ and IIEF scores when compared to baseline during annual follow-ups. Symptomatic relief from LUTS was achieved within 2 weeks of PUL while erectile and ejaculatory functions were preserved up to 5 years after PUL. It also had minimal adverse urinary symptoms and most were seen in the first 3 months postoperatively, e.g., dysuria (9%) and urge incontinence (3%). The rate of dysuria decreased to 1% after 3 months, while the rate of urge incontinence dropped to 1% after 2 years [9••, 60–62]. Another study by McVary et al. reported an improvement in ejaculatory function with a 4% improved ability to ejaculate, 23% improved ejaculation intensity and 22% increase in ejaculate volume while the BPH6 study demonstrated the superiority of PUL to TURP with regard to quality of recovery and preservation of ejaculatory function as measured by the SHIM score [63, 64]. Thus, the current literature unanimously supports the claim that this tissue-sparing approach has modest and rapid relief of LUTS while simultaneously preserving sexual function and should be considered in patients with prostate sizes smaller than 80 g.

Convective Water Vapor Energy Ablation (Rezum®)

The recently introduced Rezum® system (NxThera, Inc., Maple Grove, MN) utilizes a platform technology that convectively delivers stored thermal energy created with radiofrequency current in the form of water vapor to targeted prostatic tissue, producing instantaneous cell death [65]. This procedure is similar in concept to TUNA, but rather than using conductive energy, the Rezum® has better efficacy with regard to delivering thermal energy to heat and ablation of targeted prostatic tissue via convection. Rezum® has been shown to produce significant, rapid, and durable responses to LUTS while preserving sexual function in patients. Patients may be catheterized based on physician preference or if they develop urinary retention. A 2015 study by Dixon et al. showed that 36 out of 65 patients required catheterization prior to discharge with a mean duration of 5.6 days and an additional 11 required catheterizations after discharge, mainly due to urinary retention [66].

The largest and longest prospective cohort conducted by Roehrborn and McVary et al. reports a total of 136 patients with follow-up outcomes of up to 4 years [67••]. The authors report a < 3% risk of anejaculation after the procedure but this completely resolved by 3 months. There was also a 2.9% incidence of decreased ejaculatory volume, but this decreased to 1.5% by 3 months [68, 69]. Sexual function evaluated with IIEF and MSHQ-EjD-Function remained durable over the course of 2 years while MSHQ-EjD-Bother score remained significantly improved over 3 years [10]. Other prospective studies by Darson and Dixon report similar findings with no significant changes in IIEF and MSHQ-EjD scores after intervention with no de novo cases of ED reported post-procedure [65, 70]. Other retrospective and crossover studies also report a 3–6% risk of developing decreased ejaculatory volume or REj [71, 72]. Nevertheless, the true incidence of sexual dysfunction

needs to be studied further, but it does seem to be rarely reported at this stage. Overall, the Rezum® system provides durable and rapid improvement of LUTS and its impact on sexual function seems to be minimal and temporary. Future studies comparing this technology to the current gold standards should be conducted to further assess the efficacy of Rezum® in treating men with BPH secondary to LUTS.

Aquablation®

Another novel, minimally invasive technology for the treatment of LUTS in the BPH patient—Aquablation®. With patients under general anesthesia, the AquaBeam system (PROCEPT BioRobotics Inc., Redwood Shores, CA, USA) utilizes robotically assisted, high-velocity waterjets to ablate prostatic tissue with the aid of real-time transrectal ultrasound [73]. Unlike the UroLift® and Rezum®, this procedure cannot be done as an outpatient procedure but can be done in patients with an enlarged median lobe. Being the latest technology in the market for treating BPH, studies measuring the efficacy and outcomes for Aquablation® are beginning to mature. The current literature has demonstrated this procedure to be safe and effective in treating LUTS with significant improvements to IPSS, Qmax, and even sexual function parameters. Currently, the longest prospective trial conducted by Gilling et al. demonstrates promising 1-year results on sexual outcomes for this procedure. Aside from reporting significant improvement in LUTS and comparable rates of post-procedure urinary urgency and frequency to TURP, the authors also showed stable ejaculatory function in all patients after the procedure. IIEF scores were also improved in patients who underwent Aquablation®, although not significantly, except for the intercourse satisfaction subdomain [74, 75•]. Recently in early 2019, the WATER RCT also recently published its 1-year outcomes comparing between Aquablation® and TURP. While rates of anejaculation were significantly lower for Aquablation® compared to TURP (10% vs 36%, $p = 0.0003$), incidence rates for REj were also low for Aquablation® at 6% at 3 months and lower at 0.9% by 6 months. Moreover, IIEF and MSHQ-EjD scores remained stable in the cohort of men who underwent Aquablation®, compared to men who had decreased scores after undergoing TURP. By far, there has yet to be any reported case of ED with Aquablation® therapy [76, 77•].

Prostatic Artery Embolization

PAE is a minimally invasive, radiology-based, endovascular treatment performed for LUTS secondary to BPH. While longer-term studies are still required for this intervention, current evidence demonstrates that this method can be a safe and effective treatment even in patients with prostate sizes > 80 g who are not ideal candidates for surgery. However, it is contraindicated in patients with tortuous iliac or prostatic vasculature and in those with severe atherosclerotic disease. This procedure involves the introduction and aggregation of spherical particles within the arterial lumen, occluding blood supply and resulting in shrinkage of the prostate gland and amelioration of LUTS. This procedure has an immediate effect in decreasing prostate volume with studies reporting a mean difference of about -17 cm^3 in the first month postoperatively. Studies show this number at 1 year to be from -15 to -31 cm^3 . In terms of PSA changes, a summary of several studies shows a mean difference of -1.5 to 0.3 ng/mL , 1 month after the procedure and -2.5 to 0 ng/mL , 1 year post operatively. In terms of functional outcomes, several studies have shown significant and

A study by Albaugh et al. surveyed 27 prostate cancer patients who underwent surgery or radiation therapy and experienced sexual dysfunction within 5 years after the procedure. Most of them wished they had known more about the negative sexual issues that they would have to face after undergoing the procedure, which would have better prepared them for the likely consequences. Some participants also felt that their providers were overly optimistic with their post-treatment sexual function. While most of the affected patients wanted more resources from their providers to help with their problem, many of them discussed the importance of having a strong social support system which was paramount to their recovery. Although this study only looked at patients with prostate cancer, many of these principles are similar in nature and can be applied interchangeably to patients after BPH surgery [90].

Furthermore, the more recent, minimally invasive therapies should be thoroughly discussed with the patient as an alternative to TURP, PVP, or HoLEP. While TURP has been the gold standard BPH treatment, an increasing number of urologists are opting for other procedures, especially with many of the newer advances having similar surgical outcomes with TURP and significantly fewer sexual adverse effects. Patients should be aware of the availability of such procedures to be able to make an informed decision regarding their desired procedure type. While some procedures may be limited in certain regions or may come with increased costs, a shared decision-making approach should be utilized to seek the ideal procedure type, consistent with the patient's ideas and goals. As a provider, being knowledgeable about the latest BPH therapies and having a list of providers that offer alternative treatments will also be beneficial for the patient.

Additionally, trends show that urologists have been moving away from TURP. A 2019 Australian study analyzing Australian Medicare records showed that TURP made up 96% of surgeries from 1998 to 2008. This dropped to 73% from 2008 to 2014. In 2014 to 2017, 15.5% of procedures were PVP and 7.7% and 5.9% were UroLift® and HoLEP, respectively [91]. A similar decline in the rate of TURP was seen in America with a drop of 47.6% from 2000 to 2008, in favor of PVP, TUNA, and TUMT [92].

Conclusions

There has recently been a multitude of innovative surgical technologies for the treatment of BPH and LUTS. TURP remains the gold standard for the treatment of BPH but is associated with high rates of EjD. Thus, patients should be counseled appropriately regarding the potential reduction in postoperative sexual function. Minimally invasive procedures should also be discussed as an alternative, especially in patients who wish to preserve their sexual function. These novel technologies are a promising option to patients and have demonstrated safe, effective, and durable cure to treating BPH symptoms while minimizing sexual dysfunction. Ultimately, as the robust and dynamic field of BPH treatment continues to grow and advance, an individualized, shared decision-making approach among physicians and their patients should be undertaken to select the optimal treatment option for each patient. Regardless of the outcome of the procedure, providers should always be ready to support and assist patients in their journey to recovery.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

- Of major importance

1. Roehrborn CG. Benign prostatic hyperplasia: an overview. *Rev Urol.* 2005;7(Suppl 9):S3–S14.
2. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). *Eur Urol.* 2003;44(6):637–49. [PubMed: 14644114]
- 3••. Borchert A, Leavitt DA. A review of male sexual health and dysfunction following surgical treatment for benign prostatic hyperplasia and lower urinary tract symptoms. *Curr Urol Rep.* 2018;19(8):66. 10.1007/s11934-018-0813-0. [PubMed: 29923036] This comprehensive review summarizes post-procedural sexual dysfunction after utility of current treatment modalities available for BPH.
4. Calais Da Silva F, Marquis P, Deschaseaux P, Gineste JL, Cauquil J, Patrick DL. Relative importance of sexuality and quality of life in patients with prostatic symptoms. Results of an international study. *Eur Urol.* 1997;31(3):272–80. [PubMed: 9129915]
5. Alloussi SH, Lang C, Eichel R, Alloussi S. Ejaculation-preserving transurethral resection of prostate and bladder neck: short- and long-term results of a new innovative resection technique. *J Endourol.* 2014;28(1):84–9. 10.1089/end.2013.0093. [PubMed: 23952037]
6. Kim M, Song SH, Ku JH, Kim HJ, Paick JS. Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate. *Int J Impot Res.* 2015;27(1):20–4. 10.1038/ijir.2014.22. [PubMed: 25007827]
7. Talab SS, Santiago-Lastra YA, Bachmann A, Choi BB, Muir GH, Woo HH, et al. V403 the impact of ejaculation-preserving photo-selective vaporization of the prostate (EP-PVP) on lower urinary tract symptoms and ejaculatory function: results of a multicenter study. *J Urol.* 2013;189(4S):e164. 10.1016/j.juro.2013.02.1792.
8. Wang P, Xia D, Ye S, Kong D, Qin J, Jing T, et al. Robotic-assisted urethra-sparing simple prostatectomy via an extraperitoneal approach. *Urology.* 2018;119:85–90. 10.1016/j.urology.2018.06.005. [PubMed: 29908868]
- 9••. Roehrborn CG, Barkin J, Gange SN, Shore ND, Giddens JL, Bolton DM, et al. Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. *Can J Urol.* 2017;24(3):8802–13. [PubMed: 28646935] This prospective, randomized controlled trial is the landmark study evaluating the efficacy of UroLift of up to 5 years.
10. McVary KT, Roehrborn CG. Three-year outcomes of the prospective, randomized controlled Rez m system study: convective radiofrequency thermal therapy for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Urology.* 2018;111:1–9. 10.1016/j.urology.2017.10.023. [PubMed: 29122620]
11. Kasivisvanathan V, Hussain M. Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes. *Can J Urol.* 2018;25(3):9317–22. [PubMed: 29900819]
12. Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. *J Vasc Interv Radiol.* 2016;27(8):1115–22. 10.1016/j.jvir.2016.04.001. [PubMed: 27321890]
13. Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. *J Urol.* 2013;189(4):1421–6. 10.1016/j.juro.2012.11.003. [PubMed: 23142202]
14. Porpiglia F, Fiori C, Bertolo R, Giordano A, Checcucci E, Garrou D, et al. 3-year follow-up of temporary implantable nitinol device implantation for the treatment of benign prostatic obstruction. *BJU Int.* 2018;122(1):106–12. 10.1111/bju.14141. [PubMed: 29359881]

15. Fan Y-H, Lin A, Huang E, Chen K-K. Health care-seeking behavior in benign prostatic hyperplasia patients. *Urol Sci.* 2017;28(3):169–73.
16. Catania JA, Oakley LP, Rosen R, Pollack LM. Effects of interview mode on assessments of erectile and ejaculatory dysfunction among men with benign prostatic hyperplasia (BPH). *J Sex Res.* 2013;50(6):524–36. 10.1080/00224499.2012.666815. [PubMed: 22524285]
17. Cornell LF, Mussallem DM, Gibson TC, Diehl NN, Bagaria SP, McLaughlin SA. Trends in sexual function after breast cancer surgery. *Ann Surg Oncol.* 2017;24(9):2526–38. 10.1245/s10434-017-5894-3. [PubMed: 28560595]
18. Gil-Vernet JM, Alvarez-Vijande R, Gil-Vernet A. Ejaculation in men: a dynamic endorectal ultrasonographical study. *Br J Urol.* 1994;73(4):442–8. [PubMed: 8199835]
19. Bruyère F. The relationship between photoselective vaporization of the prostate and sexual function. *Curr Urol Rep.* 2011;12(4):261–4. 10.1007/s11934-011-0199-8. [PubMed: 21656206]
20. Pavone C, Abbadessa D, Scaduto G, Caruana G, Scalici Gesolfo C, Fontana D, et al. Sexual dysfunctions after transurethral resection of the prostate (TURP): evidence from a retrospective study on 264 patients. *Arch Ital Urol Androl.* 2015;87(1):8–13. 10.4081/aiua.2015.1.8. [PubMed: 25847889]
21. Muntener M, Aellig S, Kuettel R, Gehrlach C, Sulser T, Strebel RT. Sexual function after transurethral resection of the prostate (TURP): results of an independent prospective multicentre assessment of outcome. *Eur Urol.* 2007;52(2):510–5. 10.1016/j.eururo.2007.01.088. [PubMed: 17306446]
22. Chung A, Woo HH. Preservation of sexual function when relieving benign prostatic obstruction surgically: can a trade-off be considered? *Curr Opin Urol.* 2016;26(1):42–8. 10.1097/MOU.0000000000000247. [PubMed: 26555693]
23. Becher EF, McVary KT. Surgical procedures for BPH/LUTS: impact on male sexual health. *Sex Med Rev.* 2014;2(1):47–55. 10.1002/smrj.20. [PubMed: 27784543]
24. Bruyère F, Puichaud A, Pereira H, Faivre d’Arcier B, Rouanet A, Floc’h AP, et al. Influence of photoselective vaporization of the prostate on sexual function: results of a prospective analysis of 149 patients with long-term follow-up. *Eur Urol.* 2010;58(2):207–11. 10.1016/j.eururo.2010.04.027. [PubMed: 20466480]
25. Coursey JW, Morey AF, McAninch JW, Summerton DJ, Secrest C, White P, et al. Erectile function after anterior urethroplasty. *J Urol.* 2001;166(6):2273–6. [PubMed: 11696750]
26. Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. *J Urol.* 2018;200(3):612–9. 10.1016/j.juro.2018.05.048. [PubMed: 29775639]
27. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. 1989. *J Urol.* 2002;167(2 Pt 2):999–1003 discussion 4. [PubMed: 11908420]
28. Marra G, Sturch P, Oderda M, Tabatabaei S, Muir G, Gontero P. Systematic review of lower urinary tract symptoms/benign prostatic hyperplasia surgical treatments on men’s ejaculatory function: time for a bespoke approach? *Int J Urol.* 2016;23(1):22–35. 10.1111/iju.12866. [PubMed: 26177667] This review examines the effect of current surgical therapies and minimally invasive procedures for BPH on ejaculatory function.
29. Donovan JL, Peters TJ, Neal DE, Brookes ST, Gujral S, Chacko KN, et al. A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: the CLasP study. *J Urol.* 2000;164(1):65–70. [PubMed: 10840426]
30. Taher A. Erectile dysfunction after transurethral resection of the prostate: incidence and risk factors. *World J Urol.* 2004;22(6): 457–60. 10.1007/s00345-004-0449-1. [PubMed: 15503048]
31. Møller-Nielsen C, Lundhus E, Møller-Madsen B, Nørgaard JP, Simonsen OH, Hansen SL, et al. Sexual life following ‘minimal’ and ‘total’ transurethral prostatic resection. *Urol Int.* 1985;40(1): 3–4. 10.1159/000281022. [PubMed: 2579496]
32. Mamoulakis C, Skolarikos A, Schulze M, Scoffone CM, Rassweiler JJ, Alivizatos G, et al. Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual

- function in an international randomized controlled trial setting. *BJU Int.* 2013;112(1):109–20. 10.1111/j.1464-410X.2012.11662.x. [PubMed: 23490008]
33. Chen Q, Zhang L, Fan QL, Zhou J, Peng YB, Wang Z. Bipolar transurethral resection in saline vs traditional monopolar resection of the prostate: results of a randomized trial with a 2-year follow-up. *BJU Int.* 2010;106(9):1339–43. 10.1111/j.1464-410X.2010.09401.x. [PubMed: 20477825]
 34. El-Assmy A, ElShal AM, Mekkawy R, El-Kappany H, Ibrahiem EHI. Erectile and ejaculatory functions changes following bipolar versus monopolar transurethral resection of the prostate: a prospective randomized study. *Int Urol Nephrol.* 2018;50(9):1569–76. 10.1007/s11255-018-1950-6. [PubMed: 30083842]
 35. Friebe RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE, Wang R. The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: a systematic review. *Asian J Androl.* 2010;12(4):500–8. 10.1038/aja.2010.33 [PubMed: 20473318] This systematic review of randomized controlled trials and cohort studies report the impact of male sexual function of minimally invasive surgeries when compared to TURP.
 36. Keehn A, Fram E, Garg M, Maria P. UroLift in place of fiducial markers for patients with benign prostatic hyperplasia undergoing external beam radiation therapy. *Urology.* 2017;104:230–4. 10.1016/j.urology.2016.11.029. [PubMed: 27988266]
 37. Mock S, Leapman M, Stock RG, Hall SJ, Stone NN. Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters. *J Urol.* 2013;190(5):1805–10. 10.1016/j.juro.2013.05.010. [PubMed: 23669568]
 38. Gillig PJ, Kennett K, Das AK, Thompson D, Fraundorfer MR. Holmium laser enucleation of the prostate (HoLEP) combined with transurethral tissue morcellation: an update on the early clinical experience. *J Endourol.* 1998;12(5):457–9. 10.1089/end.1998.12.457. [PubMed: 9847070]
 39. Kuntz RM, Lehrich K, Ahyai SA. Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. *Eur Urol.* 2008;53(1):160–6. 10.1016/j.eururo.2007.08.036. [PubMed: 17869409]
 40. Meng F, Gao B, Fu Q, Chen J, Liu Y, Shi B, et al. Change of sexual function in patients before and after Ho:YAG laser enucleation of the prostate. *J Androl.* 2007;28(2):259–61. 10.2164/jandrol.106.000372. [PubMed: 17021335]
 41. Briganti A, Naspro R, Gallina A, Salonia A, Vavassori I, Hurler R, et al. Impact on sexual function of holmium laser enucleation versus transurethral resection of the prostate: results of a prospective, 2-center, randomized trial. *J Urol.* 2006;175(5):1817–21. 10.1016/S0022-5347(05)00983-3. [PubMed: 16600770]
 42. Zong HT, Peng XX, Yang CC, Zhang Y. The impact of transurethral procedures for benign prostate hyperplasia on male sexual function: a meta-analysis. *J Androl.* 2012;33(3):427–34. 10.2164/jandrol.111.013490. [PubMed: 21868751]
 43. DeLay KJ, Nutt M, McVary KT. Ejaculatory dysfunction in the treatment of lower urinary tract symptoms. *Transl Androl Urol.* 2016;5(4):450–9. 10.21037/tau.2016.06.06. [PubMed: 27652217] This review examines the effect of current surgical therapies and minimally invasive procedures for BPH on ejaculatory function.
 44. Bachmann A, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, et al. 180-W XPS GreenLight laser vaporisation versus transurethral resection of the prostate for the treatment of benign prostatic obstruction: 6-month safety and efficacy results of a European Multicentre Randomised Trial—the GOLIATH study. *Eur Urol.* 2014;65(5):931–42. 10.1016/j.eururo.2013.10.040. [PubMed: 24331152]
 45. Thomas JA, Tubaro A, Barber N, d'Ancona F, Muir G, Witzsch U, et al. A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study. *Eur Urol.* 2016;69(1):94–102. 10.1016/j.eururo.2015.07.054. [PubMed: 26283011]
 46. Spaliviero M, Strom KH, Gu X, Araki M, Culkin DJ, Wong C. Does Greenlight HPS™ laser photoselective vaporization prostatectomy affect sexual function? *J Endourol.* 2010;24(12):2051–7. 10.1089/end.2010.0296. [PubMed: 20964486]

47. Elshal AM, Elmansy HM, Elkoushy MA, Elhilali MM. Male sexual function outcome after three laser prostate surgical techniques: a single center perspective. *Urology*. 2012;80(5):1098–104. 10.1016/j.urology.2012.08.001. [PubMed: 23107401]
48. Kavoussi PK, Hermans MR. Maintenance of erectile function after photoselective vaporization of the prostate for obstructive benign prostatic hyperplasia. *J Sex Med*. 2008;5(11):2669–71. 10.1111/j.1743-6109.2008.00978.x. [PubMed: 18785895]
49. Li Z, Chen P, Wang J, Mao Q, Xiang H, Wang X, et al. The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function: a systematic review and network meta-analysis. *Medicine (Baltimore)*. 2016;95(24): e3862 10.1097/MD.0000000000003862. [PubMed: 27310968]
50. Pohnholzer A, Madersbacher S. Lower urinary tract symptoms and erectile dysfunction; links for diagnosis, management and treatment. *Int J Impot Res*. 2007;19(6):544–50. 10.1038/sj.ijir.3901578. [PubMed: 17611608]
51. Bruskewitz R, Issa MM, Roehrborn CG, Naslund MJ, Perez-Marrero R, Shumaker BP, et al. A prospective, randomized 1-year clinical trial comparing transurethral needle ablation to transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia. *J Urol*. 1998;159(5):1588–93; discussion 93–4. 10.1097/00005392-199805000-00048. [PubMed: 9554360]
52. Ahmed M, Bell T, Lawrence WT, Ward JP, Watson GM. Transurethral microwave thermotherapy (Prostatron version 2.5) compared with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a randomized, controlled, parallel study. *Br J Urol*. 1997;79(2):181–5. [PubMed: 9052467]
53. Cimentepe E, Unsal A, Saglam R. Randomized clinical trial comparing transurethral needle ablation with transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: results at 18 months. *J Endourol*. 2003;17(2):103–7. 10.1089/08927790360587432. [PubMed: 12689404]
54. Hill B, Belville W, Bruskewitz R, Issa M, Perez-Marrero R, Roehrborn C, et al. Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial. *J Urol*. 2004;171(6 Pt 1):2336–40. [PubMed: 15126816]
55. Herberts M, Butcher M, Köhler T. The effect of LUTS/BPH and treatments on ejaculatory function. *Curr Urol Rep*. 2016;17(7):48 10.1007/s11934-016-0604-4. [PubMed: 27105993] This review examines the effect of current surgical therapies and minimally invasive procedures for BPH on ejaculatory function.
56. Cantwell AL, Bogache WK, Richardson SF, Tutrone RF, Barkin J, Fagelson JE, et al. Multicentre prospective crossover study of the ‘prostatic urethral lift’ for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *BJU Int*. 2014;113(4):615–22. 10.1111/bju.12540. [PubMed: 24765680]
57. Chin PT, Bolton DM, Jack G, Rashid P, Thavaseelan J, Yu RJ, et al. Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*. 2012;79(1):5–11. 10.1016/j.urology.2011.10.021. [PubMed: 22202539]
58. Woo HH, Bolton DM, Laborde E, Jack G, Chin PT, Rashid P, et al. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Sex Med*. 2012;9(2):568–75. 10.1111/j.1743-6109.2011.02568.x. [PubMed: 22172161]
59. Shore N, Freedman S, Gange S, Moseley W, Heron S, Tutrone R, et al. Prospective multi-center study elucidating patient experience after prostatic urethral lift. *Can J Urol*. 2014;21(1):7094–101. [PubMed: 24529008]
60. Roehrborn CG. Prostatic urethral lift: a unique minimally invasive surgical treatment of male lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urol Clin North Am*. 2016;43(3): 357–69. 10.1016/j.ucl.2016.04.008. [PubMed: 27476128]
61. Roehrborn CG, Rukstalis DB, Barkin J, Gange SN, Shore ND, Giddens JL, et al. Three year results of the prostatic urethral L.I.F.T. study. *Can J Urol*. 2015;22(3):7772–82. [PubMed: 26068624]
62. Roehrborn CG, Gange SN, Shore ND, Giddens JL, Bolton DM, Cowan BE, et al. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement

- due to benign prostatic hyperplasia: the L.I.F.T. study. *J Urol*. 2013;190(6):2161–7. 10.1016/j.juro.2013.05.116. [PubMed: 23764081]
63. McVary KT, Gange SN, Shore ND, Bolton DM, Cowan BE, Brown BT, et al. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. *J Sex Med*. 2014;11(1):279–87. 10.1111/jsm.12333. [PubMed: 24119101]
64. Sønksen J, Barber NJ, Speakman MJ, Berges R, Wetterauer U, Greene D, et al. Prospective, randomized, multinational study of prostatic urethral lift versus transurethral resection of the prostate: 12-month results from the BPH6 study. *Eur Urol*. 2015;68(4):643–52. 10.1016/j.eururo.2015.04.024. [PubMed: 25937539]
65. Darson MF, Alexander EE, Schiffman ZJ, Lewitton M, Light RA, Sutton MA, et al. Procedural techniques and multicenter postmarket experience using minimally invasive convective radiofrequency thermal therapy with Rez m system for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *Res Rep Urol*. 2017;9:159–68. 10.2147/RRU.S143679. [PubMed: 28861405]
66. Dixon C, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Efficacy and safety of Rez m system water vapor treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. *Urology*. 2015;86(5):1042–7. 10.1016/j.urology.2015.05.046. [PubMed: 26216644]
- 67•. McVary KT, Rogers T, Roehrborn CG. Rez m water vapor thermal therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia: 4-year results from randomized controlled study. *Urology*. 2019 10.1016/j.urology.2018.12.041. This prospective, randomized controlled study is the landmark study evaluating the efficacy of Rezum of up to 4 years.
68. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Minimally invasive prostate convective water vapor energy ablation: a multicenter, randomized, controlled study for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. *J Urol*. 2016;195(5):1529–38. 10.1016/j.juro.2015.10.181. [PubMed: 26614889]
69. McVary KT, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study. *J Sex Med*. 2016;13(6):924–33. 10.1016/j.jsxm.2016.03.372. [PubMed: 27129767]
70. Dixon CM, Cedano ER, Pacik D, Vit V, Varga G, Wagrell L, et al. Two-year results after convective radiofrequency water vapor thermal therapy of symptomatic benign prostatic hyperplasia. *Res Rep Urol*. 2016;8:207–16. 10.2147/RRU.S119596. [PubMed: 27921028]
71. Mollengarden D, Goldberg K, Wong D, Roehrborn C. Convective radiofrequency water vapor thermal therapy for benign prostatic hyperplasia: a single office experience. *Prostate Cancer Prostatic Dis*. 2018;21(3):379–85. 10.1038/s41391-017-0022-9. [PubMed: 29282358]
72. Roehrborn CG, Gange SN, Gittelman MC, Goldberg KA, Patel K, Shore ND, et al. Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. *J Urol*. 2017;197(6):1507–16. 10.1016/j.juro.2016.12.045. [PubMed: 27993667]
73. MacRae C, Gilling P. How I do it: aquablation of the prostate using the AQUABEAM system. *Can J Urol*. 2016;23(6):8590–3. [PubMed: 27995858]
74. Gilling P, Reuther R, Kahokehr A, Fraundorfer M. Aquablation - image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. *BJU Int*. 2016;117(6):923–9. 10.1111/bju.13358. [PubMed: 26477826]
- 75•. Gilling P, Anderson P, Tan A. Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. *J Urol*. 2017;197(6):1565–72. 10.1016/j.juro.2017.01.056 [PubMed: 28111300] This prospective single arm study aimed to assess the safety and efficacy of aquablation.
76. Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. WATER: a double-blind, randomized, controlled trial of aquablation. *J Urol*. 2018;199(5):1252–61. 10.1016/j.juro.2017.12.065. [PubMed: 29360529]
- 77•. Gilling PJ, Barber N, Bidair M, Anderson P, Sutton M, Aho T, et al. Randomized controlled trial of aquablation versus transurethral re-section of the prostate in benign prostatic hyperplasia: one-year outcomes. *Urology*. 2019;125:169–73. 10.1016/j.urology.2018.12.002. [PubMed: 30552937]

This study reports the most recent 1 year outcomes comparing the safety and efficacy of aquablation to TURP.

78. Kurbatov D, Russo GI, Lepetukhin A, Dubsy S, Sitkin I, Morgia G, et al. Prostatic artery embolization for prostate volume greater than 80 cm³: results from a single-center prospective study. *Urology*. 2014;84(2):400–4. 10.1016/j.urology.2014.04.028. [PubMed: 24929948]
79. Li Q, Duan F, Wang MQ, Zhang GD, Yuan K. Prostatic arterial embolization with small sized particles for the treatment of lower urinary tract symptoms due to large benign prostatic hyperplasia: preliminary results. *Chin Med J*. 2015;128(15):2072–7. 10.4103/0366-6999.161370. [PubMed: 26228221]
80. Wang MQ, Guo LP, Zhang GD, Yuan K, Li K, Duan F, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms due to large (>80 mL) benign prostatic hyperplasia: results of midterm follow-up from Chinese population. *BMC Urol*. 2015;15:33 10.1186/s12894-015-0026-5. [PubMed: 25887036]
81. Isaacson AJ, Raynor MC, Yu H, Burke CT. Prostatic artery embolization using embosphere microspheres for prostates measuring 80–150 cm³: early results from a US trial. *J Vasc Interv Radiol*. 2016;27(5):709–14. 10.1016/j.jvir.2016.01.146. [PubMed: 27106645]
82. Bagla S, Smirniotopoulos JB, Orlando JC, van Breda A, Vadlamudi V. Comparative analysis of prostate volume as a predictor of outcome in prostate artery embolization. *J Vasc Interv Radiol*. 2015;26(12):1832–8. 10.1016/j.jvir.2015.08.018. [PubMed: 26428880]
83. Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms as a result of large benign prostatic hyperplasia: a prospective single-center investigation. *Int J Urol*. 2015;22(8):766–72. 10.1111/iju.12797. [PubMed: 25950927]
84. Pisco J, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Prostate embolization as an alternative to open surgery in patients with large prostate and moderate to severe lower urinary tract symptoms. *J Vasc Interv Radiol*. 2016;27(5):700–8. 10.1016/j.jvir.2016.01.138. [PubMed: 27019980]
85. Wang M, Guo L, Duan F, Yuan K, Zhang G, Li K, et al. Prostatic arterial embolization for the treatment of lower urinary tract symptoms caused by benign prostatic hyperplasia: a comparative study of medium- and large-volume prostates. *BJU Int*. 2016;117(1):155–64. 10.1111/bju.13147. [PubMed: 25851432]
86. Wang XY, Zong HT, Zhang Y. Efficacy and safety of prostate artery embolization on lower urinary tract symptoms related to benign prostatic hyperplasia: a systematic review and meta-analysis. *Clin Interv Aging*. 2016;11:1609–22. 10.2147/CIA.S119241. [PubMed: 27956827]
87. Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). *BJU Int*. 2018;122(2):270–82. 10.1111/bju.14249. [PubMed: 29645352]
88. Pham H, Sharma P. Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy. *Can J Urol*. 2018;25(2):9228–37. [PubMed: 29679999]
89. Bowen DK, Butcher MJ, Botchway A, McVary KT. Counseling on sexual side effects from TURP. *Can J Urol*. 2015;22(6):8063–8. [PubMed: 26688134]
90. Albaugh JA, Sufrin N, Lapin BR, Petkewicz J, Tenfelde S. Life after prostate cancer treatment: a mixed methods study of the experiences of men with sexual dysfunction and their partners. *BMC Urol*. 2017;17(1):45 10.1186/s12894-017-0231-5. [PubMed: 28619019]
91. Patel RM, Bariol S. National trends in surgical therapy for benign prostatic hyperplasia in Australia. *ANZ J Surg*. 2019;89(4):345–9. 10.1111/ans.15016. [PubMed: 30706655]
92. Malaeb BS, Yu X, McBean AM, Elliott SP. National trends in surgical therapy for benign prostatic hyperplasia in the United States (2000–2008). *Urology*. 2012;79(5):1111–6. 10.1016/j.urology.2011.11.084. [PubMed: 22546389]

Table 1

Risk of sexual dysfunction after various BPH treatments

Procedure	Risk of postoperative sexual dysfunction
Transurethral resection of prostate (TURP)	REj 38.2–89.0%
	PE 0–2.0%
	DV 18.3–54.0%
Holmium laser enucleation of the prostate (HoLEP)	ED 13.0–14.0%
	REj 50.0–76.6%
	PE 3.3%
Photoselective vaporization of the prostate (PVP)	DV 16.7%
	ED 5.2–7.9%
	REj 21.4–49.9%
Transurethral needle ablation (TUNA)	PE 5.4%
	ED 0–20.9%
	REj 0–5.6%
Transurethral microwave therapy (TUMT)	DV 13.0%
	ED 5.8%
	REj 9.2–24.0%
Prostatic urethral lift (UroLift®)	ED 0–18.2%
Convective water vapor energy ablation (Rezum®)	N/A
Aquablation®	DV 2.9%
	AE 2.9%
Prostatic artery embolization (PAE)	REj 10.0%
	REj 24.1%

REj retrograde ejaculation, PE painful ejaculation, DV decreased volume of ejaculate, ED erectile dysfunction, AE anejaculation

Table 2
Current BPH treatment options and their related postoperative sexual dysfunction

Procedure	Procedure description	Effect on sexual function	FDA approval; insurance coverage
Transurethral resection of prostate (TURP)	Monopolar or bipolar electrocautery is used to resect prostatic adenoma with a resectoscope.	High rates of ejaculatory dysfunction. Modified technique that spares the paracollicular and supracollicular tissue had 91% of patients maintain anterograde ejaculation on 5-year follow-up [5].	Yes; considered the gold standard for most insurance policies.
Holmium laser enucleation of the prostate (HoLEP)	Uses a laser to enucleate the prostate, which is then morcellated prior to removal.	High rates of ejaculatory dysfunction. Modified technique that spares the paracollicular and supracollicular tissue shown to not affect ejaculatory outcomes [6].	Yes; covered by Medicare, but other insurance providers require prior authorization.
Photoselective vaporization of the prostate (PVP)	Utilization of laser energy to vaporize prostate tissue.	High rates of ejaculatory dysfunction. Modified technique preserving bladder neck muscle fibers, precollicular tissue and paracollicular prostate tissue had 13% of 160 with anejaculation and 31% with decreased ejaculation [7].	Medicare requires patients to have: <ul style="list-style-type: none"> • BPH for a duration of > 3 months • AUA symptom score > 9 • Urodynamics or post-void residual volume showing bladder outlet obstruction
Simple prostatectomy	Removal of the prostate via open, laparoscopic or robotic approach.	Robotic outcomes with urethral sparing approach reported 1 out of 14 patients developing retrograde ejaculation [8].	N/A
Prostatic urethral lift (UroLift®)	Attachment of nitinol and stainless steel intra-prostatic implants to the lateral lobes of the prostate to reduce bladder outlet obstruction.	Unaffected sexual function after 5 years of follow-up in 206 patients [9•].	Yes; covered by Medicare, other insurance providers require prior authorization to determine that procedure is indicated (prostate volume < 80 cc, no obstructive median lobe).
Convective water vapor energy ablation (Rezum®)	Technique that uses convective radiofrequency water vapor thermal energy to disrupt prostatic cell membranes and ablate prostatic tissue.	Minimally affected sexual function with 3 years of follow-up in 197 patients [10].	Yes; covered by Medicare, but other insurance providers require prior authorization.
Aquablation®	Removal of prostate tissue with high-velocity waterjets under the guidance of transrectal ultrasonography.	In a landmark study, rate of anejaculation was 9% with Aquablation® vs 45% in TURP [11].	Yes; most insurance companies see this treatment as experimental and recommend seeking prior authorization.
Prostatic artery embolization (PAE)	Injection of polyvinyl alcohol (PVA) particles to occlude the prostatic arteries and decrease the volume of the prostate with time.	In study of 630 patients, average IIEF score change was + 1.17 points +/- 5.74. Score was decreased in 36.5% of patients (average reduction 3.84 points +/- 3.18) [12].	Yes; requires pre-authorization. Coverage depends on patient's symptoms and type of insurance.
PRX302 intra-prostatic injection	Pore-forming protein activated by prostate-specific antigen (PSA) that is injected into the prostate to cause cell death in the prostate tissue.	No sexual adverse effects after 12-month follow-up in 92 patients [13].	No; This device is currently undergoing clinical trials to assess safety and efficacy.
Temporary implantable nitinol device (TIND)	Device that creates incisions in the prostate to reshape the urethra and bladder neck and reduce bladder outlet obstruction.	No ejaculatory dysfunction after 3-year follow-up in 19 patients [14].	No; This device is currently undergoing clinical trials to assess safety and efficacy.